newYou can now listen to Fox News articles!
The World Health Organization (WHO) on Friday recommended two monoclonal antibody treatments against Ebola, saying that the combined use of such drugs and better care could “revolutionize” the treatment of a disease once considered a probable cause of death. caused,” he said.
Regeneron’s Inmazeb (REGN-EB3) and Ridgeback Bio’s Ebanga (mAb114) use lab-made monoclonal antibodies that mimic natural antibodies in fighting off infections.
Deadly Ebola-like Marburg virus could ‘widespread’ if not stopped: WHO
“Advancements in supportive care and treatment over the past decade have revolutionized Ebola treatment. Ebola virus disease was perceived as a probable killer. says university professor Robert Fowler. He is Mayor of Toronto, Canada and co-chairs the WHO’s Guideline Development Group. Effective care and the use of these treatments have now led to the recovery of the “majority” of people from Ebola, he said, though he did not provide specific data.
Ebola hemorrhagic fever can remain in survivors for 5 years before triggering new outbreak
The new recommendations follow trials of the drug against hemorrhagic fevers in the Democratic Republic of the Congo in 2018-2020. Dr Janet Diaz, head of clinical management for the WHO’s health emergencies programme, told journalists that while drugs are now available in Congo, more work is needed to improve affordability. He said there is